Premium
Open‐label phase 2 study of faldaprevir, deleobuvir and ribavirin in Japanese treatment‐naive patients with chronic hepatitis C virus genotype 1 infection
Author(s) -
Yatsuhashi Hiroshi,
Kodani Nobuyoshi,
Ugai Hiroyuki,
Omata Masao
Publication year - 2016
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12535
Subject(s) - ribavirin , medicine , adverse effect , nausea , gastroenterology , vomiting , clinical endpoint , hepatitis c virus , virology , virus , clinical trial
Aim The safety and efficacy of the NS3/4A protease inhibitor faldaprevir in combination with the non‐nucleoside NS5B polymerase inhibitor deleobuvir and ribavirin in Japanese treatment‐naive patients with chronic genotype 1 hepatitis C virus (HCV) infection was evaluated. Methods In this multicenter, open‐label phase 2 study, patients were assigned to 8 weeks of treatment with 80 mg (group 1) or 120 mg (group 2) faldaprevir once daily (q.d.) in combination with deleobuvir 600 mg twice daily and weight‐based ribavirin. This was followed by a 24‐week treatment with faldaprevir 120 mg q.d. in combination with peginterferon‐α‐2a and ribavirin. The primary objective was safety; virological response at weeks 4 and 8 was a secondary endpoint. Results Twelve and 13 patients were treated in group 1 and 2, respectively; all were infected with HCV genotype 1b. All patients experienced a drug‐related adverse event (AE). The frequency of individual events was generally numerically greater in group 2 than 1. The most common AEs were nausea (66.7%, group 1; 76.9%, group 2) and vomiting (33.3%, group 1; 61.5%, group 2). Virological response at weeks 4 and 8 was achieved by 11 (91.7%) patients in group 1; in group 2, 12 (92.3%) patients achieved virological response at week 4 and all at week 8. All patients who achieved the week 8 endpoint achieved sustained virological response at week 12. Conclusion Faldaprevir 80 or 120 mg q.d. in combination with deleobuvir and ribavirin was tolerable and had similar efficacy in Japanese patients with HCV genotype 1 infection. ClinicalTrials.gov: NCT01528735.